Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

15 Lymphoma cells from a pleural effusion in a pediatric patient with T-cell lymphoblastic disease at relapse were obtained from Morgan Stanley Children's Hospital of New York-Presbyterian ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...

Marshall Davies, 21, from Telford, was diagnosed with a rare and potentially aggressive type of cutaneous T-cell lymphoma in April 2023. In December he received the news it had progressed to ...

T-cell or NK-cell clones. Subclones of these cells may acquire independent genetic changes to produce non-Hodgkin lymphomas and Hodgkin lymphoma. Another speculation is that the multiclonal ...

The asset in question, an autologous CAR-T dubbed ASP2802 aimed at CD20-positive B-cell lymphomas, had been undergoing a phase 1 trial to determine a suitable dose for further studies as well as ...

Table 2. Distinction between atypical lymphoid proliferations rich in Reed–Sternberg-like cells (reactive immunoblasts) and classic Hodgkin lymphomas. Aspects Atypical lymphoid proliferations ...